Epidemiological and clinical profiles of cutaneous leishmaniasis cases in Amhara National Regional State, Northwest Ethiopia: a multicenter retrospective study
https://doi.org/10.4081/dr.2024.10089
Accepted: 31 August 2024
HTML: 10
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Cutaneous leishmaniasis (CL) is caused by Leishmania parasites. Ethiopia is one of the top ten countries with a high CL load, and Amhara National Regional State (ANRS) is one of the CL hotspot areas in the country. This study examined cutaneous leishmaniasis’s epidemiology and clinical profiles in the ANRS region. It was conducted from April to October 2023 across eight Leishmaniasis Treatment Centres (LTCs). A data review was done from patients presenting to these centers between June 2018 and July 2023. Chi-square test and logistic regression were performed using SPSS-23. A total of 1729 patients with CL were recorded, resulting in an overall burden of 8.6 cases per 10,000 outpatients. Patients were from 112 districts, and most of them (71.1%) presented with localized cutaneous leishmaniasis (LCL). Approximately 12% of patients lived with the disease for over a year without treatment, while 13.2% of patients were multiple-time comers. Cutaneous leishmaniasis continues to be a significant public health issue in the ANRS region. Approximately onethird of CL patients exhibit the mucocutaneous leishmaniasis (MCL) clinical form. There has been a notable delay among CL patients in seeking diagnosis and treatment. It is essential to conduct large-scale community-based studies and studies focused on both traditional and modern treatment centers to accurately estimate the prevalence of CL in the region. Follow-up and molecular studies are crucial for enhancing our understanding of the clinical features of the disease. Furthermore, raising community awareness about CL prevention and control can help patients obtain early diagnosis and treatment.
Ruiz-Postigo JA, Grout L, Jain S. Global leishmaniasis surveillance, 2017–2018, and first report on 5 additional indicators Weekly epidemiological record 2020;25:165-280.
Singh OP, Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol 2014;5:296.
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018;392:951-70.
World Health Organization (WHO). Leishmaniasis 2022.
den Boer M, Argaw D, Jannin J, et al. Leishmaniasis impact and treatment access. Clin Microbiol Infect 2011;17:1471-7.
Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96.
Neitzke-Abreu HC, Venazzi MS, de Lima Scodro RB, et al. Cutaneous leishmaniasis with atypical clinical manifestations: Case report. IDCases 2014;1:60-2.
Gómez LJ, van Wijk R, van Selm L, et al. Stigma, participation restriction and mental distress in patients affected by leprosy, cutaneous leishmaniasis and Chagas disease: a pilot study in two co-endemic regions of eastern Colombia. Trans R Soc Trop Med Hyg 2019:1-7.
Bennis I, Thys S, Filali H, et al. Psychosocial impact of scars due to cutaneous leishmaniasis on high school students in Errachidia province, Morocco. Infect Dis Poverty 2017;6:46.
Mengistu G, Laskay T, Gemetchu T, et al. Cutaneous leishmaniasis in south-western Ethiopia: Ocholo revisited. Trans R Soc Trop Med Hyg 1992;86:149-53.
Yizengaw E, Nibret E, Yismaw G, et al. Cutaneous leishmaniasis in a newly established treatment centre in the Lay Gayint district, Northwest Ethiopia. Skin Health Dis 2023:1-8.
Shita EY, Nibret E, Munshea A, et al. Burden and risk factors of cutaneous leishmaniasis in Ethiopia: a systematic review and meta-analysis. Int J Dermatol 2022;61:1336-45.
Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-319.
Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7:e35671.
Guideline for Diagnosis, Treatment and Prevention of Leishmaniasis in Ethiopia 2013.
Gashaw G. Yizengaw E, Sebsibe B, et al. Clinical Manifestations of Cutaneous Leishmaniasis (CL): Does Elevated Blood Sugar Level have Implications for Clinical Management of CL? Ethiop J Health Dev 2023;37.
Eshetu B, Mamo H. Cutaneous leishmaniasis in north-central Ethiopia: trend, clinical forms, geographic distribution, and determinants. Trop Med Health 2020;48:39.
van Henten S, Bialfew F, Hassen S, et al.Treatment of cutaneous leishmaniasis with sodium stibogluconate and allopurinol in a routine setting in Ethiopia: Clinical and Patient-Reported Outcomes and Operational Challenges. Trop Med Infect Dis 2023;8.
Neway BYS, Mebrat B, Ayalew G. Prevalence of cutaneous leishmaniasis in alert center, retrospective analysis, Addis Ababa. J Health Syst Policies. 2021;3:110-21.
van Henten S, Adriaensen W, Fikre H, et al. Cutaneous Leishmaniasis Due to Leishmania aethiopica. EClinicalMedicine 2018;6:69-81.
Fikre H, Mohammed R, Atinafu S, et al. Clinical features and treatment response of cutaneous leishmaniasis in North-West Ethiopia. Trop Med Int Health 2017;22:1293-301.
Yohannes M, Abebe Z, Boelee E. Prevalence and environmental determinants of cutaneous leishmaniasis in rural communities in Tigray, northern Ethiopia. PLoS Negl Trop Dis 2019;13:e0007722.
Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 2015;282:20143085.
Davies CR, Gavgani ASM. Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology 1999;119:247-57.
Okwor I, Mou Z, Liu D, et al. Protective immunity and vaccination against cutaneous leishmaniasis. Front Immunol 2012;3:128.
Seife AKBT, Zewdu TF, Ayal A, et al. Treatment Patterns and Effectivness of Anti-Leishmaniasis Agents for Patients with Cutaneous Leishmaniasis at Boru Meda Hospital, South Wollo, North East Ethiopia, 2017/18. J Clin Exp Dermatol Res 2018;9.
Negera E, Gadisa E, Yamuah L, et al. Outbreak of cutaneous leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification. Trans R Soc Trop Med Hyg 2008;102:883-90.
Tilahun WAT, Mulatu G. Magnitude and associated factors of cutaneous leishmaniasis; in Mekelle city, Ayder referral hospital, Tigray, Northern Ethiopia, 2014. Clin Med Res 2014;3.
Bisetegn H, Zeleke AJ, Gadisa E, et al. Clinical, parasitological and molecular profiles of Cutaneous Leishmaniasis and its associated factors among clinically suspected patients attending Borumeda Hospital, North-East Ethiopia. PLoS Negl Trop Dis 2020;14:e0008507.
van Henten S, Tesfaye AB, Abdela SG, et al. Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia. PLoS Negl Trop Dis 2021;15:e0009460.
Cantanhede LM, da Silva Junior CF, Ito MM, et al. Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients. PLoS Negl Trop Dis 2015;9:e0004079.
Aberra L, Abera A, Belay T, et al. Evaluation of microcapillary culture method for the isolation of Leishmania aethiopica parasites from patients with cutaneous lesions in Ethiopia. Diagn Progn Res 2019;3:4.
Lemma A, Foster WA, Gemetchu T, et al. A Studies on leishmaniasis in Ethiopia. I. Preliminary investigations into the epidemiology of cutaneous leishmaniasis in the highlands. Ann Trop Med Parasitol 1969;63:455-72.
Padovese V, Terranova M, Toma L, et al. Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. Trans R Soc Trop Med Hyg 2009;103:707-11.
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
